Riding on the back of an improved regulatory environment in China, major Japanese drug makers are moving to expand their businesses in the world’s second largest pharma market. Companies are pumping up their new drug pipelines, while forging solid sales…
HOME > BUSINESS
BUSINESS
- Shionogi's FY2018 Sales Up 5.5% on HIV Royalties, Xofluza Notches 26.3 Billion Yen
May 10, 2019
- Ono Chief Touts 3-Pronged Recipe for Opdivo Comeback as I/O Pioneer
May 10, 2019
- Eisai to Invest 15 Billion Yen to Excavate Innovative Technology; 1st Pact Signed with App Developer
May 10, 2019
- Takeda to Divest Dry Eye Drug to Novartis for US$5.3 Billion
May 9, 2019
- Japan Generic Makers Cutting Back on New Grad Hiring in Near-Saturated Market: Jiho Survey
May 9, 2019
- Kissei Braced for 65% Sales Fall for Urief on Generic Onslaught; Exec Admits Uphill Battle for Nesp Biosimilar
May 9, 2019
- Sumitomo Dainippon to Set Up Cell Therapy Hub in San Diego
May 9, 2019
- DS-8201 Delivers in PII Breast Cancer Study: Daiichi Sankyo/AZ
May 9, 2019
- Eisai Kicks Off Joint Program with UK Institution to Support Dementia Research
May 9, 2019
- Bioverativ Japan Now Merged into Sanofi
May 8, 2019
- Eisai, Purdue Wind Up Partnership for Insomnia Drug Lemborexant
May 8, 2019
- Shionogi, AI Startup Tie Up to Develop Influenza Diagnostic Device
May 8, 2019
- Japan Generic Market to Reach 1.2 Trillion Yen by 2022, Biosimilars, AG Market to Expand Too: Fuji Keizai
May 7, 2019
- Daiichi Sankyo Skips Pre-Verification for Vaccine Sterility Test, No Safety Concerns Found
May 7, 2019
- Boehringer Workforce Dwindles by 500 in Japan, MSD by 300: Jiho Survey
May 7, 2019
- Dupixent Now Available for Self-Injection
May 7, 2019
- Daiichi Sankyo Exercises Option to Commercialize Bispecific Antibodies Based on Joint Research with Zymeworks
May 7, 2019
- After Biogen Pullout, Salix Picks Up Rights to Mitsubishi Tanabe’s MT-1303
May 7, 2019
- Dupixent Filed for Sinusitis in Japan: Sanofi
May 7, 2019
- Astellas Looks to Fortify China Biz via Global Commercial Rejig
April 26, 2019
ページ
The female manager ratio at foreign drug makers in Japan has been on the steady rise since the enforcement in April 2016 of the Act on Promotion of Women’s Participation and Career Advancement in the Workplace. Women now account for…
As Japan heralds the new imperial era of Reiwa, Eisai CEO Haruo Naito sat with Jiho to look back on…
Japan’s generic market is hitting a plateau soon. Incentive measures rolled out by the government since 2002 have driven its…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Manufacturers of regenerative medicine-based products are beginning to differentiate themselves from competitors based not only on efficacy but also on the reduction of burdens on medical institutions where their therapies are provided.The procedures required for administering regenerative medicine products are…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
Earlier this year, I attended a conference discussing the trends of Japan’s pharmaceutical industry. The objective of the conference was to determine what Japanese pharmaceutical companies were doing, and what they could be doing, to make themselves more competitive on…